ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad protection against infectious diseases, and its scientific founders at Belgium’s VIB, Flanders’ leading life sciences institute, today announced the publication of a pre-print paper by De Cae et al., entitled “Ultrapotent .
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.
/PRNewswire/ ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the.